-
3
-
-
37549072095
-
-
Fort Washington, PA: National Comprehensive Cancer Network, Available at: Last accessed 14 May 2014
-
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology - Kidney Cancer version 3.2014. Fort Washington, PA: National Comprehensive Cancer Network, 2014. Available at: http://www.nccn.org/professionals/physician-gls/pdf/kidney.pdf [Last accessed 14 May 2014]
-
(2014)
NCCN Clinical Practice Guidelines in Oncology - Kidney Cancer Version 3.2014
-
-
-
4
-
-
70249097380
-
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
-
Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol Off J Am Soc Clin Oncol 2009;27:3312-18
-
(2009)
J Clin Oncol Off J Am Soc Clin Oncol
, vol.27
, pp. 3312-3318
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
-
5
-
-
77952300540
-
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival
-
Escudier B, Bellmunt J, Né grier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol Off J Am Soc Clin Oncol 2010;28:2144-50
-
(2010)
J Clin Oncol Off J Am Soc Clin Oncol
, vol.28
, pp. 2144-2150
-
-
Escudier, B.1
Bellmunt, J.2
Né Grier, S.3
-
6
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
-
(2007)
N Engl J Med
, vol.356
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
7
-
-
77949890945
-
Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial
-
Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol Off J Am Soc Clin Oncol 2010;28:1061-8
-
(2010)
J Clin Oncol Off J Am Soc Clin Oncol
, vol.28
, pp. 1061-1068
-
-
Sternberg, C.N.1
Davis, I.D.2
Mardiak, J.3
-
8
-
-
34249779568
-
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
-
Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81
-
(2007)
N Engl J Med
, vol.356
, pp. 2271-2281
-
-
Hudes, G.1
Carducci, M.2
Tomczak, P.3
-
9
-
-
77956227464
-
Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors
-
Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256-65
-
(2010)
Cancer
, vol.116
, pp. 4256-4265
-
-
Motzer, R.J.1
Escudier, B.2
Oudard, S.3
-
10
-
-
82755183572
-
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial
-
Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:1931-9
-
(2011)
Lancet
, vol.378
, pp. 1931-1939
-
-
Rini, B.I.1
Escudier, B.2
Tomczak, P.3
-
11
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell carcinoma
-
Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
-
(2007)
N Engl J Med
, vol.356
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
-
12
-
-
84899679988
-
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma
-
Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 2014;32:760-7
-
(2014)
J Clin Oncol Off J Am Soc Clin Oncol
, vol.32
, pp. 760-767
-
-
Hutson, T.E.1
Escudier, B.2
Esteban, E.3
-
13
-
-
84896713052
-
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: An open-label, randomised phase 3 trial
-
Motzer RJ, Porta C, Vogelzang NJ, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:286-96
-
(2014)
Lancet Oncol
, vol.15
, pp. 286-296
-
-
Motzer, R.J.1
Porta, C.2
Vogelzang, N.J.3
-
14
-
-
80255141916
-
Sequence therapy in patients with metastatic renal cell carcinoma: Comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors
-
Busch J, Seidel C, Kempkensteffen C, et al. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur Urol 2011;60:1163-70
-
(2011)
Eur Urol
, vol.60
, pp. 1163-1170
-
-
Busch, J.1
Seidel, C.2
Kempkensteffen, C.3
-
15
-
-
84868515033
-
Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma
-
Chen C-C, Hess GP, Liu Z, et al. Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma. Clin Genitourin Cancer 2012;10:256-61
-
(2012)
Clin Genitourin Cancer
, vol.10
, pp. 256-261
-
-
Chen, C.-C.1
Hess, G.P.2
Liu, Z.3
-
16
-
-
84866294721
-
Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: Evidence from US community oncology clinics
-
Feinberg BA, Jolly P, Wang S-T, et al. Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. Med Oncol Northwood Lond Engl 2012;29:786-94
-
(2012)
Med Oncol Northwood Lond Engl
, vol.29
, pp. 786-794
-
-
Feinberg, B.A.1
Jolly, P.2
Wang, S.-T.3
-
17
-
-
84880267774
-
Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI
-
Park K, Lee J-L, Park I, et al. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI. Med Oncol Northwood Lond Engl 2012;29:3291-7
-
(2012)
Med Oncol Northwood Lond Engl
, vol.29
, pp. 3291-3297
-
-
Park, K.1
Lee, J.-L.2
Park, I.3
-
18
-
-
77955470097
-
Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy
-
Vickers MM, Choueiri TK, Rogers M, et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 2010;76:430-4
-
(2010)
Urology
, vol.76
, pp. 430-434
-
-
Vickers, M.M.1
Choueiri, T.K.2
Rogers, M.3
-
19
-
-
84867519699
-
Immunotherapy and targeted therapies in metastatic renal cell carcinoma: Is there a preferred sequence?
-
Giuliani J, Drudi F. Immunotherapy and targeted therapies in metastatic renal cell carcinoma: is there a preferred sequence? Cancer Biother Radiopharm 2012;27:513-18
-
(2012)
Cancer Biother Radiopharm
, vol.27
, pp. 513-518
-
-
Giuliani, J.1
Drudi, F.2
-
20
-
-
79955122842
-
Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action
-
Larkin J, Swanton C, Pickering L. Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. Expert Rev Anticancer Ther 2011;11:639-49
-
(2011)
Expert Rev Anticancer Ther
, vol.11
, pp. 639-649
-
-
Larkin, J.1
Swanton, C.2
Pickering, L.3
-
21
-
-
84871514484
-
Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: State-of-the-science
-
Porta C, Sabbatini R, Procopio G, et al. Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. Expert Rev Anticancer Ther 2012;12:1571-7
-
(2012)
Expert Rev Anticancer Ther
, vol.12
, pp. 1571-1577
-
-
Porta, C.1
Sabbatini, R.2
Procopio, G.3
-
22
-
-
84896470513
-
Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: A US medical record review
-
Wong MK, Yang H, Signorovitch JE, et al. Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review. Curr Med Res Opin 2014;30:537-45
-
(2014)
Curr Med Res Opin
, vol.30
, pp. 537-545
-
-
Wong, M.K.1
Yang, H.2
Signorovitch, J.E.3
-
23
-
-
79958734431
-
An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples
-
Di Lorenzo G, Casciano R, Malangone E, et al. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. Expert Opin Pharmacother 2011;12:1491-7
-
(2011)
Expert Opin Pharmacother
, vol.12
, pp. 1491-1497
-
-
Di Lorenzo, G.1
Casciano, R.2
Malangone, E.3
-
24
-
-
84878495150
-
A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC)
-
Heng D. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2012;30(Suppl 5): abstr 387
-
(2012)
J Clin Oncol
, vol.30
-
-
Heng, D.1
-
25
-
-
84887021715
-
Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective U.S. chart review
-
Yang H, Wong MKK, Signorovitch JE, et al. Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: a retrospective U.S. chart review. J Clin Oncol 2012;30:(suppl): abstr 4612
-
(2012)
J Clin Oncol
, vol.30
-
-
Yang, H.1
Wong, M.K.K.2
Signorovitch, J.E.3
-
26
-
-
84995400026
-
Second-line prescribing preferences (PPrefs) of U.S.-based medical oncologists (MOs) following first-line TKI in patients with metastatic clear cell renal cell carcinoma (mccRCC)
-
Ryan CJ, Green MR, Britton SL, et al. Second-line prescribing preferences (PPrefs) of U.S.-based medical oncologists (MOs) following first-line TKI in patients with metastatic clear cell renal cell carcinoma (mccRCC). J Clin Oncol 2014;32(suppl 4): abstr 492
-
(2014)
J Clin Oncol
, vol.32
-
-
Ryan, C.J.1
Green, M.R.2
Britton, S.L.3
-
27
-
-
84908641368
-
Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: Synthesis of findings from two multi-practice chart reviews in the United States
-
in press
-
Signorovitch JE, Vogelzang NJ, Pal SK, et al. Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States. Curr Med Res Opin 2014, in press
-
(2014)
Curr Med Res Opin
-
-
Signorovitch, J.E.1
Vogelzang, N.J.2
Pal, S.K.3
|